Bevacizumab Therapy for Brain Arteriovenous Malformation

Part of paid clinical trials in San Francisco, California.

Sponsor
University of California, San Francisco
Study ID
NCT02314377
Phase
PHASE1
Status
Completed

Conditions

  • Brain Arteriovenous Malformation

Eligibility Criteria

Sex
ALL
Age
18 Years - 64 Years
Healthy Volunteers
Not accepted

Interventions

  • Bevacizumab — DRUG
    Bevacizumab dosing of 5mg/kg q 2 weeks for 12 weeks (2.5 mg/week).

Study Details

Bevacizumab Therapy for brain arteriovenous malformation that is not amenable to surgical intervention.

Key Dates

First listed
Dec 11, 2014
Start date
Jun 30, 2016
Status verified
Feb 2020
Primary completion
Dec 1, 2018
Completion
Dec 1, 2019

Study Design

Enrollment
2 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: AVM treatment with Bevacizumab
    Bevacizumab infusion dose of 5mg/kg q 2 weeks for 12 weeks (2.5 mg/week).

Primary Outcome Measure

Our primary outcome will be change in AVM volume from pre-treatment MRI. [ Time Frame: 12, 26 and 52 weeks ]

Locations (1)

FacilityCityStateZIPSite coordinators
University of California San FranciscoSan FranciscoCalifornia94143-

Find similar trials in San Francisco, CA

By research site
University of California San Francisco· San Francisco, CA